Home/Biosimilar Atlas/Rituximab/Real World Evidence

Rituximab biosimilars: real-world and switching evidence

What the evidence shows

Evidence intelligence
3published studies
1trial with a single switch
2real-world cohorts
2diseases covered
2products covered
  • Studies found3 studies: the extension of the CT-P10 phase 3 trial, in which 109 rheumatoid arthritis patients moved from MabThera or Rituxan to Truxima, and two cohorts from routine care in rheumatology.
  • Biggest studyItalian centres moved 181 patients with rheumatoid arthritis and other autoimmune rheumatic diseases from MabThera to a biosimilar, mostly Rixathon. Eight in ten were still on the biosimilar after a year and nearly the same after three.
  • Products with evidenceRixathon, Truxima. No published switching study yet in this register for Ruxience, Riabni or the Indian products.
  • What is missingNo study from India or the Gulf. Nothing in lymphoma or leukaemia, where most rituximab is used. No trial with repeated switching.

Studies

Disease
Product

Trials and extensions with a single switch

Patients on MabThera in a trial were moved once to the biosimilar, usually at the half-way point, and followed alongside those who stayed.

StudyDiseaseSwitchProductsPatients switchedFollow-upWhat the authors report
Shim 2019
Rheumatology (Oxford) 2019;58(12):2193-2202
Multinational, multicentre
Rheumatoid arthritisSingle switch, reference (US- or EU-sourced) to biosimilarTruxima10972 weeksMean change in DAS28-CRP from baseline at week 72 was -3.0, -3.0, -2.9 and -3.0 in the CT-P10, reference, US-reference-to-CT-P10 and EU-reference-to-CT-P10 groups; ACR responses and quality of life improvements similar; two patients developed new anti-drug antibodies in the extension; pharmacodynamics and safety similar across groups.
Shim 2019Rheumatology (Oxford) 2019;58(12):2193-2202
DiseaseRheumatoid arthritisSwitchSingle switch, reference (US- or EU-sourced) to biosimilarProductsTruximaPatients109Follow-up72 weeks
What the authors report

Mean change in DAS28-CRP from baseline at week 72 was -3.0, -3.0, -2.9 and -3.0 in the CT-P10, reference, US-reference-to-CT-P10 and EU-reference-to-CT-P10 groups; ACR responses and quality of life improvements similar; two patients developed new anti-drug antibodies in the extension; pharmacodynamics and safety similar across groups.

No study matches this selection.

Real-world cohorts

Switches carried out in hospitals and national programmes, with outcomes taken from registries and patient records.

StudyDiseaseSwitchProductsPatients switchedFollow-upWhat the authors report
Gentileschi 2024
Ther Adv Musculoskelet Dis 2024;16
Multicentre, Italy (2018 to 2020)
Autoimmune rheumatic diseases (rheumatoid arthritis and connective tissue diseases)Originator to biosimilar (non-medical)Rixathon, Truxima181Mean 17 monthsRetention on the biosimilar 81.5% at 12 months, 80.6% at 24 months and 77.4% at 36 months; retention higher with GP2013 than CT-P10 (p<0.001); no difference by diagnosis or sex.
Losinska 2023
Rheumatol Int 2023;43(5):881-888
Rheumatology outpatient clinic, Norway (single centre, 2018 to 2021)
Rheumatoid arthritisOriginator to biosimilar (non-medical, mandatory)Rixathon88Up to 2 yearsOverall drug survival 80.0% at one year and 57.7% at two years, higher in switched than in biosimilar-naive patients (p=0.036); most discontinuations were for remission (38.6%) or doctor decision (27.1%).
Gentileschi 2024Ther Adv Musculoskelet Dis 2024;16
DiseaseAutoimmune rheumatic diseases (rheumatoid arthritis and connective tissue diseases)SwitchOriginator to biosimilar (non-medical)ProductsRixathon, TruximaPatients181Follow-upMean 17 months
What the authors report

Retention on the biosimilar 81.5% at 12 months, 80.6% at 24 months and 77.4% at 36 months; retention higher with GP2013 than CT-P10 (p<0.001); no difference by diagnosis or sex.

Losinska 2023Rheumatol Int 2023;43(5):881-888
DiseaseRheumatoid arthritisSwitchOriginator to biosimilar (non-medical, mandatory)ProductsRixathonPatients88Follow-upUp to 2 years
What the authors report

Overall drug survival 80.0% at one year and 57.7% at two years, higher in switched than in biosimilar-naive patients (p=0.036); most discontinuations were for remission (38.6%) or doctor decision (27.1%).

No study matches this selection.

Switching evidence is what regulators, tender committees and formulary boards ask for before a change of product. EvySaif prepares interchangeability and switching dossiers and designs real-world studies for biosimilar programmes. Regulatory strategy consulting

Sources

Planning rituximab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.